

PATIENT NAME : HEMA MADHURI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0181XC001432 PATIENT ID : HEMAF170195181 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 29 Years Female DRAWN : RECEIVED : 29/03/2024 07:55:06 REPORTED : 30/03/2024 16:29:05	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY	DIBETEIC SINCE 4-5 YEARS.
RELEVANT PAST HISTORY	NOT SIGNIFICANT
RELEVANT PERSONAL HISTORY	MARRIED / MIXED DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.
MENSTRUAL HISTORY (FOR FEMALES)	27/3-4.
LMP (FOR FEMALES)	02/03/2024.
OBSTETRIC HISTORY (FOR FEMALES)	2LSCSA1L2.
RELEVANT FAMILY HISTORY	DIABTES.
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS	1.59	mts
WEIGHT IN KGS.	66	Kgs
BMI	26	kg/sqmts

BMI & Weight Status as follows
 Below 18.5: Underweight
 18.5 - 24.9: Normal
 25.0 - 29.9: Overweight
 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 S.K. Tower, Hari Niwas, Lbs Marg
 Thane, 400602
 Maharashtra, India
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI**REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHINEW DELHI 110030
8800465156ACCESSION NO : **0181XC001432**

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

PHYSICAL ATTITUDE	NORMAL		
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY		
BUILT / SKELETAL FRAMEWORK	AVERAGE		
FACIAL APPEARANCE	NORMAL		
SKIN	NORMAL		
UPPER LIMB	NORMAL		
LOWER LIMB	NORMAL		
NECK	NORMAL		
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER		
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
TEMPERATURE	NORMAL		
PULSE	96/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT		
RESPIRATORY RATE	NORMAL		

CARDIOVASCULAR SYSTEM

BP	126/80 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST	NORMAL
MOVEMENTS OF CHEST	SYMMETRICAL
BREATH SOUNDS INTENSITY	NORMAL
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)
ADDED SOUNDS	ABSENT



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
S.K. Tower, Hari Niwas, Lbs Marg
Thane, 400602
Maharashtra, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval Units

PER ABDOMEN

APPEARANCE	NORMAL
VENOUS PROMINENCE	ABSENT
LIVER	NOT PALPABLE
SPLEEN	NOT PALPABLE
HERNIA	ABSENT

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS	NORMAL
CRANIAL NERVES	NORMAL
CEREBELLAR FUNCTIONS	NORMAL
SENSORY SYSTEM	NORMAL
MOTOR SYSTEM	NORMAL
REFLEXES	NORMAL

MUSCULOSKELETAL SYSTEM

SPINE	NORMAL
JOINTS	NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY 6/12

Page 3 Of 25



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 S.K. Tower, Hari Niwas, Lbs Marg
 Thane, 400602
 Maharashtra, India
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956


Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0181XC001432 PATIENT ID : HEMAF170195181 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 29 Years Female DRAWN : RECEIVED : 29/03/2024 07:55:06 REPORTED : 30/03/2024 16:29:05	

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY 6/12
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
COLOUR VISION	NORMAL

SUMMARY

RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT
REMARKS / RECOMMENDATIONS	FOLLOW UP WITH PHYSICIAN FOR B.SUGAR CONTROL & TREATMENT OF DYSLIPIDEMIA. STRICT LOW FAT,LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET. REGULAR EXERCISE.REGULAR WALK FOR 30-40 MIN DAILY. REPEAT LIPID PROFILE, BLOOD SUGAR AFTER 3 MONTHS OF DIET AND EXERCISE. OPHTHALMOLOGY CONSULT FOR REDUCED VISUAL ACUITY.



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
S.K. Tower, Hari Niwas, Lbs Marg
Thane, 400602
Maharashtra, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0181XC001432 PATIENT ID : HEMAF170195181 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 29 Years Female DRAWN : RECEIVED : 29/03/2024 07:55:06 REPORTED : 30/03/2024 16:29:05	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE
ULTRASOUND ABDOMEN
ULTRASOUND ABDOMEN
 GRADE I FATTY LIVER.

TMT OR ECHO
CLINICAL PROFILE
 NEGATIVE

Interpretation(s)
 MEDICAL HISTORY-*****
 THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report
 Please visit www.agilusdiagnostics.com for related Test Information for this accession



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 S.K. Tower, Hari Niwas, Lbs Marg
 Thane, 400602
 Maharashtra, India
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



PATIENT NAME : HEMA MADHURI**REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : **0181XC001432**

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status Final**Results****Biological Reference Interval****Units****CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
S.K. Tower, Hari Niwas, Lbs Marg
Thane, 400602
Maharashtra, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID :

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval Units

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS, EDTA WHOLE BLOOD

Parameter	Result	Biological Reference Interval	Units
HEMOGLOBIN (HB) METHOD : SLS- HEMOGLOBIN DETECTION METHOD	13.3	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION	5.01 High	3.8 - 4.8	mil/ μ L
WHITE BLOOD CELL (WBC) COUNT METHOD : FLUORESCENCE FLOW CYTOMETRY	9.75	4.0 - 10.0	thou/ μ L
PLATELET COUNT METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION	493 High	150 - 410	thou/ μ L

RBC AND PLATELET INDICES

HEMATOCRIT (PCV) METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD	41.9	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED FROM RBC & HCT	83.6	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED FROM THE RBC & HGB	26.5 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED FROM THE HGB & HCT	31.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE	12.4	11.6 - 14.0	%
MENTZER INDEX	16.7		
MEAN PLATELET VOLUME (MPV) METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT	9.5	6.8 - 10.9	fL

WBC DIFFERENTIAL COUNT

NEUTROPHILS METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	57	40 - 80	%
LYMPHOCYTES METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	36	20 - 40	%
MONOCYTES	5	2 - 10	%



Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 7 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

EOSINOPHILS

2

1 - 6

%

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

BASOPHILS

0

0 - 1

%

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

ABSOLUTE NEUTROPHIL COUNT

5.56

2.0 - 7.0

thou/ μ L

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

ABSOLUTE LYMPHOCYTE COUNT

3.49 High

1.0 - 3.0

thou/ μ L

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

ABSOLUTE MONOCYTE COUNT

0.50

0.2 - 1.0

thou/ μ L

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

ABSOLUTE EOSINOPHIL COUNT

0.16

0.02 - 0.50

thou/ μ L

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

ABSOLUTE BASOPHIL COUNT

0.00 Low

0.02 - 0.10

thou/ μ L

METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING

NEUTROPHIL LYMPHOCYTE RATIO (NLR)

1.6

MORPHOLOGY

RBC

NORMOCYTIC NORMOCHROMIC

WBC

NORMAL MORPHOLOGY

METHOD : MICROSCOPIC EXAMINATION

PLATELETS

INCREASED

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD - The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES - Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait.

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT - The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.)



Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 8 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ACCESSION NO : 0181XC001432

AGE/SEX : 29 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

PATIENT ID : HEMAF170195181

DRAWN :

NEW DELHI 110030
8800465156

CLIENT PATIENT ID:

RECEIVED : 29/03/2024 07:55:06

ABHA NO :

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval

Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA
BLOOD

E.S.R 9 0 - 20 mm

METHOD : MODIFIED WESTERGRÉN

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE
BLOOD

HBA1C 9.8 High

Non-diabetic Adult < 5.7 %
Pre-diabetes 5.7 - 6.4
Diabetes diagnosis: > or = 6.5
Therapeutic goals: < 7.0
Action suggested : > 8.0
(ADA Guideline 2021)

METHOD : HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 234.6 High < 116.0 mg/dL

METHOD : CALCULATED PARAMETER

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (> 100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemia, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(Sickle Cells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACCPress, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



Dr.(Mrs)Neelu K Bhojani
Lab Head

Page 9 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India

Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0181XC001432 PATIENT ID : HEMAF170195181 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 29 Years Female DRAWN : RECEIVED : 29/03/2024 07:55:06 REPORTED : 30/03/2024 16:29:05
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
 2. Diagnosing diabetes.
 3. Identifying patients at increased risk for diabetes (prediabetes).
- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods,falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in
 - a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 - b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 - c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr.(Mrs)Neelu K Bhojani
Lab Head



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

 CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

 ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05
Test Report Status **Final**

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE AB

METHOD : GEL COLUMN AGGLUTINATION METHOD.

RH TYPE

POSITIVE

METHOD : GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



 Dr.(Mrs)Neelu K Bhojani
 Lab Head

Page 11 Of 25



View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Mulund Goregoan Link Road
 Mumbai, 400078
 Maharashtra, India
 Fax :
 CIN - U74899PB1995PLC045956


Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0181XC001432 PATIENT ID : HEMAF170195181 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 29 Years Female DRAWN : RECEIVED : 29/03/2024 07:55:06 REPORTED : 30/03/2024 16:29:05	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	232 High	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
----------------------------------	-----------------	--	-------

METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	199 High	70 - 139	mg/dL
--	-----------------	----------	-------

METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL	233 High	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
---------------------------	-----------------	---	-------

METHOD : ENZYMATIC COLORIMETRIC ASSAY

TRIGLYCERIDES	197 High	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: > / = 500	mg/dL
----------------------	-----------------	--	-------

METHOD : ENZYMATIC COLORIMETRIC ASSAY

HDL CHOLESTEROL	47	At Risk: < 40 Desirable: > or = 60	mg/dL
------------------------	-----------	---------------------------------------	-------

METHOD : ENZYMATIC, COLORIMETRIC

CHOLESTEROL LDL	147 High	Adult levels: Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL
------------------------	-----------------	--	-------

METHOD : ENZYMATIC COLORIMETRIC ASSAY

Dr. Ushma Wartikar
Consultant Pathologist

Dr. Priyal Chinchkhede
Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
Lab Head



View Details



View Report

PATIENT NAME : HEMA MADHURI **REF. DOCTOR : SELF**
 CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156
 ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :
 AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
NON HDL CHOLESTEROL		186 High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO		39.4 High 5.0 High	< OR = 30.0 Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	mg/dL
LDL/HDL RATIO		3.1 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL.	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)

Dr. Ushma Wartikar
 Consultant Pathologist

Dr. Priyal Chinchkhede
 Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
 Lab Head



View Details



View Report

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHINEW DELHI 110030
8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID :

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Extreme Risk Group Category A	<50 (Optional goal <OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR - 30	<OR - 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR- 70	>OR- 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR- 130*	>OR- 160

*After an adequate non-pharmacological intervention for at least 3 months.


References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.61	Upto 1.2	mg/dL
METHOD : COLORIMETRIC DIAZO			
BILIRUBIN, DIRECT	0.22	< 0.30	mg/dL
METHOD : DIAZO METHOD			
BILIRUBIN, INDIRECT	0.39	0.1 - 1.0	mg/dL
TOTAL PROTEIN	7.7	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC			
GLOBULIN	3.1	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	11	< OR = 35	U/L
METHOD : UV ABSORBANCE			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	8	< OR = 35	U/L
METHOD : UV ABSORBANCE			
ALKALINE PHOSPHATASE	61	35 - 104	U/L
METHOD : COLORIMETRIC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	21	0 - 40	U/L
METHOD : ENZYMATIC, COLORIMETRIC			
LACTATE DEHYDROGENASE	147	125 - 220	U/L
METHOD : UV ABSORBANCE			

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN	10	6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY			


Dr. Ushma Wartikar
Consultant Pathologist

Dr. Priyal Chinchkhede
Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 14 Of 25



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956

Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

 CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

 ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE	0.54	0.5 - 0.9	mg/dL
METHOD : COLORIMETRIC			

BUN/CREAT RATIO

BUN/CREAT RATIO	18.52 High	8.0 - 15.0	
-----------------	-------------------	------------	--

URIC ACID, SERUM

URIC ACID	4.0	2.4 - 5.7	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY			

TOTAL PROTEIN, SERUM

TOTAL PROTEIN	7.7	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC			

ALBUMIN, SERUM


ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC			

GLOBULIN

GLOBULIN	3.1	2.0 - 3.5	g/dL
----------	-----	-----------	------

ELECTROLYTES (NA/K/CL), SERUM


 Dr. Ushma Wartikar
 Consultant Pathologist



 Dr. Priyal Chinchkhede
 Consultant Pathologist



 Dr. (Mrs) Neelu K Bhojani
 Lab Head

Page 15 Of 25



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Mulund Goregoan Link Road
 Mumbai, 400078
 Maharashtra, India
 Fax :
 CIN - U74899PB1995PLC045956


Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : **0181XC001432**
PATIENT ID : HEMAF170195181
CLIENT PATIENT ID :
ABHA NO :

AGE/SEX : 29 Years Female
DRAWN :
RECEIVED : 29/03/2024 07:55:06
REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		137	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY				
POTASSIUM, SERUM		4.84	3.5 - 5.1	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY				
CHLORIDE, SERUM		100	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, antidepressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

Dr. Ushma Wartikar
Consultant Pathologist

Dr. Priyal Chinchkhede
Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
Lab Head



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138394	ACCESSION NO : 0181XC001432	AGE/SEX : 29 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : HEMAF170195181	DRAWN :	
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST	CLIENT PATIENT ID :	RECEIVED : 29/03/2024 07:55:06	
DELHI	ABHA NO :	REPORTED : 30/03/2024 16:29:05	
NEW DELHI 110030			
8800465156			

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

LIVER FUNCTION PROFILE, SERUM-Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome **Causes of decreased levels:** Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Ushma Wartikar
Consultant Pathologist

Dr. Priyal Chinchkhede
Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
Lab Head



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : **0181XC001432**
PATIENT ID : HEMAF170195181
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 29 Years Female
DRAWN :
RECEIVED : 29/03/2024 07:55:06
REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE


COLOR	PALE YELLOW
METHOD : MICROSCOPIC EXAMINATION	
APPEARANCE	CLEAR
METHOD : MICROSCOPIC EXAMINATION	

CHEMICAL EXAMINATION, URINE

PH	6.5	4.6 - 8.0
METHOD : METHYL RED & BROMOTHYMOLO BLUE		
SPECIFIC GRAVITY	1.015	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
METHOD : TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID		
GLUCOSE	NOT DETECTED	NOT DETECTED
METHOD : GLUCOSE OXIDASE / PEROXIDASE (GOD - POD) METHOD		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : SODIUM NITROPRUSSIDE REACTION		
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : STRIP TEST - DIAZONIUM SALT COUPLING		
UROBILINOGEN	NORMAL	NORMAL
METHOD : CAFFEINE BENZOATE		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : STRIP NAPHTHOETHYLENEDIAMINE HYDROCHLORIDE, TANNIC ACID		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED
METHOD : STRIP HETEROCYCLIC CARBOXYLIC ACID ESTER, DIAZONIUM SALT		

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			



Dr. Priyal Chinchkhede
Consultant Pathologist



Dr. Ushma Wartikar
Consultant Pathologist



Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 18 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

CASTS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED			
CRYSTALS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED			
BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED		
YEAST	NOT DETECTED	NOT DETECTED		

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice

Dr. Priyal Chinchkhede
 Consultant Pathologist

Dr. Ushma Wartikar
 Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
 Lab Head



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Mulund Goregoan Link Road
 Mumbai, 400078
 Maharashtra, India
 Fax :
 CIN - U74899PB1995PLC045956

Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05


Test Report Status **Final**

Results

Biological Reference Interval

Units

Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis


Dr. Priyal Chinchkhede
Consultant Pathologist

Dr. Ushma Wartikar
Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 20 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Mulund Goregoan Link Road

Mumbai, 400078

Maharashtra, India

Fax :

CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

 CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

 ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE**PAPANICOLAOU SMEAR****TEST METHOD**

METHOD : MICROSCOPIC EXAMINATION

CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE

METHOD : MICROSCOPIC EXAMINATION

P-620/24

TWO UNSTAINED CERVICAL SMEARS RECEIVED

REPORTING SYSTEM

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

SATISFACTORY

MICROSCOPY

METHOD : PAP STAIN

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS & INTERMEDIATE SQUAMOUS CELLS IN THE BACKGROUND OF FEW POLYMORPHS.


INTERPRETATION / RESULT

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

PLEASE NOTE PAPANICOLAOU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.



 Dr. Priyal Chinchkhede
 Consultant Pathologist

Page 21 Of 25



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Mulund Goregoan Link Road
 Mumbai, 400078
 Maharashtra, India
 Fax :
 CIN - U74899PB1995PLC045956


Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE**MICROSCOPIC EXAMINATION,STOOL**

REMARK

SAMPLE NOT RECEIVED

Comments

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects & reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.



Dr. Sheetal Sawant
Consultant Microbiologist

Page 22 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval Units

pH

Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS :

1. **Stool Culture**:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
2. **Fecal Calprotectin**: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
3. **Fecal Occult Blood Test (FOBT)**: This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
4. **Clostridium Difficile Toxin Assay**: This test is strongly recommended in healthcare associated bloody or watery diarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
5. **Biofire (Film Array) GI PANEL**: In patients of Diarrhoea, Dysentery, Rice watery Stool, FDA approved, Biofire Film Array Test (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
6. **Rota Virus Immunoassay**: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomiting & abdominal cramps. Adults are also affected. It is highly contagious in nature.



 Dr. Sheetal Sawant
 Consultant Microbiologist

Page 23 Of 25



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Mulund Goregoan Link Road
 Mumbai, 400078
 Maharashtra, India
 Fax :
 CIN - U74899PB1995PLC045956


Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0181XC001432

PATIENT ID : HEMAF170195181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 29 Years Female

DRAWN :

RECEIVED : 29/03/2024 07:55:06

REPORTED : 30/03/2024 16:29:05

Test Report Status **Final**

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3	125.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE			
T4	12.90	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	3.550	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.


Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically



Dr. Ushma Wartikar
Consultant Pathologist



Dr. Priyal Chinchkhede
Consultant Pathologist



Dr. (Mrs) Neelu K Bhojani
Lab Head

Page 24 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Mulund Goregoan Link Road
Mumbai, 400078
Maharashtra, India
Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 775000006985813

PATIENT NAME : HEMA MADHURI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138394
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : **0181XC001432**
 PATIENT ID : HEMAF170195181
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 29 Years Female
 DRAWN :
 RECEIVED : 29/03/2024 07:55:06
 REPORTED : 30/03/2024 16:29:05

Test Report Status **Final** Results Biological Reference Interval Units

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.
NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Ushma Wartikar
 Consultant Pathologist

Dr. Priyal Chinchkhede
 Consultant Pathologist

Dr. (Mrs) Neelu K Bhojani
 Lab Head



View Details



View Report